User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Cancer risk in immune-mediated inflammatory diseases (IMID)

Primary tabs

download
  • Open access
  • PDF
  • 212.64 K
Beyaert, Rudi Beaugerie, Laurent Van Assche, Gert Brochez, Lieve Renauld, Jean-Christophe [UCL] Machiels, Jean-Pascal [UCL] Masson, Pierre [UCL] De Keyser, Filip

Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2013
Language Anglais
Journal information "Molecular Cancer" - Vol. 12, no.1, p. 98 [1-12] (2013)
Peer reviewed yes
Publisher BioMed Central Ltd. ((United Kingdom) London)
e-issn 1476-4598
Publication status Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - (SLuc) Unité d'oncologie médicale
UCL - (SLuc) Centre du cancer
Links
  1. Grivennikov Sergei I, Karin Michael, Inflammation and oncogenesis: a vicious connection, 10.1016/j.gde.2009.11.004
  2. Solinas G., Germano G., Mantovani A., Allavena P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation, 10.1189/jlb.0609385
  3. Bui Jack D, Schreiber Robert D, Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?, 10.1016/j.coi.2007.02.001
  4. Dunn Gavin P., Old Lloyd J., Schreiber Robert D., The Three Es of Cancer Immunoediting, 10.1146/annurev.immunol.22.012703.104803
  5. Nakachi Kei, Hayashi Tomonori, Imai Kazue, Kusunoki Yoichiro, Perspectives on cancer immuno-epidemiology, 10.1111/j.1349-7006.2004.tb03178.x
  6. Shankaran Vijay, Ikeda Hiroaki, Bruce Allen T., White J. Michael, Swanson Paul E., Old Lloyd J., Schreiber Robert D., 10.1038/35074122
  7. Smyth Mark J., Thia Kevin Y. T., Street Shayna E.A., Cretney Erika, Trapani Joseph A., Taniguchi Masaru, Kawano Tetsu, Pelikan Sonja B., Crowe Nadine Y., Godfrey Dale I., Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells, 10.1084/jem.191.4.661
  8. Street Shayna E.A., Trapani Joseph A., MacGregor Duncan, Smyth Mark J., Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ, 10.1084/jem.20020063
  9. ENGEL A.-M., SVANE I. M., RYGAARD J., WERDELIN O., MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice, 10.1046/j.1365-3083.1997.d01-419.x
  10. Svane Inge Marie, Engel Anne-Marie, Nielsen Mai-Britt, Ljunggren Hans-Gustaf, Rygaard Jørgen, Werdelin Ole, Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice, 10.1002/eji.1830260827
  11. Müller-Hermelink Nele, Braumüller Heidi, Pichler Bernd, Wieder Thomas, Mailhammer Reinhard, Schaak Katrin, Ghoreschi Kamran, Yazdi Amir, Haubner Roland, Sander Christian A., Mocikat Ralph, Schwaiger Markus, Förster Irmgard, Huss Ralph, Weber Wolfgang A., Kneilling Manfred, Röcken Martin, TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis, 10.1016/j.ccr.2008.04.001
  12. Mantovani Alberto, Allavena Paola, Sica Antonio, Balkwill Frances, Cancer-related inflammation, 10.1038/nature07205
  13. Balkwill Fran, Mantovani Alberto, Inflammation and cancer: back to Virchow?, 10.1016/s0140-6736(00)04046-0
  14. Karin Michael, Greten Florian R., NF-κB: linking inflammation and immunity to cancer development and progression, 10.1038/nri1703
  15. Rothwell Peter M, Price Jacqueline F, Fowkes F Gerald R, Zanchetti Alberto, Roncaglioni Maria Carla, Tognoni Gianni, Lee Robert, Belch Jill FF, Wilson Michelle, Mehta Ziyah, Meade Tom W, Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials, 10.1016/s0140-6736(11)61720-0
  16. Jacobs E. J., Newton C. C., Gapstur S. M., Thun M. J., Daily Aspirin Use and Cancer Mortality in a Large US Cohort, 10.1093/jnci/djs318
  17. Baron J. A., Aspirin and Cancer: Trials and Observational Studies, 10.1093/jnci/djs338
  18. Pasche Boris, Differential Effects of Aspirin Before and After Diagnosis of Colorectal Cancer, 10.1001/jama.2013.6600
  19. Kaiser J., Will an Aspirin a Day Keep Cancer Away?, 10.1126/science.337.6101.1471
  20. Zumsteg Adrian, Christofori Gerhard, Corrupt policemen: inflammatory cells promote tumor angiogenesis : , 10.1097/cco.0b013e32831bed7e
  21. Pastuła Agnieszka, Marcinkiewicz Janusz, Myeloid-derived suppressor cells: a double-edged sword? : Dual role of myeloid-derived suppressor cells, 10.1111/j.1365-2613.2010.00754.x
  22. Barnes Peter J., Karin Michael, Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory Diseases, 10.1056/nejm199704103361506
  23. Hayden M. S., Ghosh S., NF- B, the first quarter-century: remarkable progress and outstanding questions, 10.1101/gad.183434.111
  24. Askling J, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists, 10.1136/ard.2004.033241
  25. Zhang Jiankang, Wu Peng, Hu Yongzhou, Clinical and Marketed Proteasome Inhibitors for Cancer Treatment, 10.2174/09298673113209990122
  26. Askling J, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists, 10.1136/ard.2004.033993
  27. Smitten Allison L, Simon Teresa A, Hochberg M C, Suissa Samy, A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis, 10.1186/ar2404
  28. Baecklund Eva, Iliadou Anastasia, Askling Johan, Ekbom Anders, Backlin Carin, Granath Fredrik, Catrina Anca Irinel, Rosenquist Richard, Feltelius Nils, Sundström Christer, Klareskog Lars, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, 10.1002/art.21675
  29. Loftus Edward V, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, 10.1053/j.gastro.2004.01.063
  30. Kristinsson S. Y., Landgren O., Samuelsson J., Bjorkholm M., Goldin L. R., Autoimmunity and the risk of myeloproliferative neoplasms, 10.3324/haematol.2009.020412
  31. Watanabe Takuya, Soga Kenji, Hirono Haruka, Hasegawa Katsuhiko, Shibasaki Koichi, Kawai Hirokazu, Aoyagi Yutaka, Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis, 10.3748/wjg.15.231
  32. Wong Robert J., Gish Robert, Frederick Todd, Bzowej Natalie, Frenette Catherine, Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series, 10.1007/s10620-010-1444-6
  33. Goldacre Michael J., Wotton Clare J., Yeates David, Seagroatt Valerie, Jewell Derek, Cancer in patients with ulcerative colitis, Crohnʼs disease and coeliac disease: record linkage study : , 10.1097/meg.0b013e3282f2a5e2
  34. Landgren Annelie M., Landgren Ola, Gridley Gloria, Dores Graça M., Linet Martha S., Morton Lindsay M., Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans, 10.1002/cncr.25524
  35. Silano Marco, , Volta Umberto, Mecchia Anna Maria, Dessì Mariarita, Di Benedetto Rita, De Vincenzi Massimo, Delayed diagnosis of coeliac disease increases cancer risk, 10.1186/1471-230x-7-8
  36. Pedersen Natalia, Duricova Dana, Elkjaer Margarita, Gamborg Michael, Munkholm Pia, Jess Tine, Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort Studies, 10.1038/ajg.2009.760
  37. Laukoetter Mike Georg, Mennigen Rudolf, Hannig C. Mareike, Osada Nani, Rijcken Emile, Vowinkel Thorsten, Krieglstein Christian F., Senninger Norbert, Anthoni Christoph, Bruewer Matthias, Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis, 10.1007/s11605-010-1402-9
  38. CANAVAN C., ABRAMS K. R., MAYBERRY J., Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, 10.1111/j.1365-2036.2006.02854.x
  39. Szekanecz Zoltán, Szekanecz Éva, Bakó Gyula, Shoenfeld Yehuda, Malignancies in Autoimmune Rheumatic Diseases – A Mini-Review, 10.1159/000314634
  40. Prizment Anna E., Alonso Alvaro, Folsom Aaron R., Ahmed Rehana L., Virnig Beth A., Warshaw Erin M., Anderson Kristin E., Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study, 10.1007/s10552-011-9773-0
  41. Hannuksela-Svahn Anna, Pukkala Eero, Läärä Esa, Poikolainen Kari, Karvonen Jaakko, Psoriasis, its Treatment, and Cancer in a Cohort of Finnish Patients, 10.1046/j.1523-1747.2000.00898.x
  42. Chen Yi-Ju, Wu Chun-Ying, Chen Tzeng-Ji, Shen Jui-Lung, Chu Szu-Ying, Wang Chang-Bi, Chang Yun-Ting, The risk of cancer in patients with psoriasis: A population-based cohort study in Taiwan, 10.1016/j.jaad.2010.04.046
  43. Lanoy E, Engels E A, Skin cancers associated with autoimmune conditions among elderly adults, 10.1038/sj.bjc.6605733
  44. Boffetta Paolo, Gridley Gloria, Lindelöf Bernt, Cancer Risk in a Population-Based Cohort of Patients Hospitalized for Psoriasis in Sweden, 10.1046/j.0022-202x.2001.01520.x
  45. Ji J, Shu X, Sundquist K, Sundquist J, Hemminki K, Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden, 10.1038/sj.bjc.6605027
  46. Söderberg Karin C., Jonsson Fredrik, Winqvist Ola, Hagmar Lars, Feychting Maria, Autoimmune diseases, asthma and risk of haematological malignancies: A nationwide case-control study in Sweden, 10.1016/j.ejca.2006.04.021
  47. Gelfand Joel M., Berlin Jesse, Van Voorhees Abby, Margolis David J., Lymphoma Rates Are Low but Increased in Patients With Psoriasis : Results From a Population-Based Cohort Study in the United Kingdom, 10.1001/archderm.139.11.1425
  48. Askling J, Risk of haematopoietic cancer in patients with inflammatory bowel disease, 10.1136/gut.2004.051771
  49. Boffetta Paolo, Rabkin Charles S., Gridley Gloria, A cohort study of cancer among sarcoidosis patients, 10.1002/ijc.24261
  50. Kiss Emese, Kovacs Laszlo, Szodoray Peter, Malignancies in systemic lupus erythematosus, 10.1016/j.autrev.2009.07.004
  51. Rosenthal Ann K., McLaughlin Joseph K., Gridley Gloria, Nyrén Olof, Incidence of cancer among patients with systemic sclerosis, 10.1002/1097-0142(19950901)76:5<910::aid-cncr2820760528>3.0.co;2-t
  52. Magruder J. Trent, Elahi Dariush, Andersen Dana K., Diabetes and Pancreatic Cancer : Chicken or Egg?, 10.1097/mpa.0b013e318209e05d
  53. Stevens R J, Roddam A W, Beral V, Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis, 10.1038/sj.bjc.6603571
  54. Soetikno Roy M., Lin Otto S., Heidenreich Paul A., Young Harvey S., Blackstone Michael O., Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis, 10.1067/mge.2002.125367
  55. Bernstein Charles N., Blanchard James F., Kliewer Erich, Wajda Andre, Cancer risk in patients with inflammatory bowel disease : A population-based study, 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
  56. THOMAS T., ABRAMS K. A., ROBINSON R. J., MAYBERRY J. F., Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis : META-ANALYSIS: CANCER RISK OF LGD IN CHRONIC UC, 10.1111/j.1365-2036.2007.03241.x
  57. Rutter M D, Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk, 10.1136/gut.2003.038505
  58. Gupta Roopali Bansal, Harpaz Noam, Itzkowitz Steven, Hossain Sabera, Matula Sierra, Kornbluth Asher, Bodian Carol, Ullman Thomas, Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort Study, 10.1053/j.gastro.2007.08.001
  59. Nestle Frank O., Kaplan Daniel H., Barker Jonathan, Psoriasis, 10.1056/nejmra0804595
  60. Naldi Luigi, Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies, 10.1016/j.clindermatol.2009.03.003
  61. Patel Rita V., Clark Lily N., Lebwohl Mark, Weinberg Jeffrey M., Treatments for psoriasis and the risk of malignancy, 10.1016/j.jaad.2008.12.031
  62. Stern Robert S., Lymphoma Risk in Psoriasis : Results of the PUVA Follow-up Study, 10.1001/archderm.142.9.1132
  63. Väkevä L, Reitamo S, Pukkala E, Sarna S, Ranki A, Long-term Follow-up of Cancer Risk in Patients Treated with Short-term Cyclosporine, 10.2340/00015555-0360
  64. Smith Paul P., Gordon Caroline, Systemic lupus erythematosus: Clinical presentations, 10.1016/j.autrev.2010.08.016
  65. Bernatsky S, Ramsey-Goldman R, Foulkes W D, Gordon C, Clarke A E, Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis, 10.1038/bjc.2011.115
  66. Dinarello Charles A., Anti-inflammatory Agents: Present and Future, 10.1016/j.cell.2010.02.043
  67. Martinez O. M., de Gruijl F. R., Molecular and Immunologic Mechanisms of Cancer Pathogenesis in Solid Organ Transplant Recipients, 10.1111/j.1600-6143.2008.02368.x
  68. Karran Peter, Attard Natalie, Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer, 10.1038/nrc2292
  69. Beaugerie Laurent, Brousse Nicole, Bouvier Anne Marie, Colombel Jean Frédéric, Lémann Marc, Cosnes Jacques, Hébuterne Xavier, Cortot Antoine, Bouhnik Yoram, Gendre Jean Pierre, Simon Tabassome, Maynadié Marc, Hermine Olivier, Faivre Jean, Carrat Fabrice, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, 10.1016/s0140-6736(09)61302-7
  70. Long Millie D., Herfarth Hans H., Pipkin Clare A., Porter Carol Q., Sandler Robert S., Kappelman Michael D., Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease, 10.1016/j.cgh.2009.11.024
  71. Kandiel A, Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, 10.1136/gut.2004.049460
  72. Setshedi Mashiko, Epstein David, Winter Trevor A, Myer Landon, Watermeyer Gillian, Hift Richard, Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study : Thiopurine use and risk of cancer, 10.1111/j.1440-1746.2011.06865.x
  73. Paul Carle F., Ho Vincent C., McGeown Claire, Christophers Enno, Schmidtmann Birgit, Guillaume Jean-Claude, Lamarque Véronique, Dubertret Louis, Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study, 10.1046/j.1523-1747.2003.12040.x
  74. Buchbinder Rachelle, Barber Melissa, Heuzenroeder Louise, Wluka Anita E., Giles Graham, Hall Stephen, Harkness Andrew, Lewis Daniel, Littlejohn Geoff, Miller Marian H., Ryan Peter F. J., Jolley Damien, Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate, 10.1002/art.23716
  75. Salliot C, van der Heijde D, Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research, 10.1136/ard.2008.093690
  76. KRATHEN M. S., GOTTLIEB A. B., MEASE P. J., Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis, 10.3899/jrheum.100041
  77. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B., An endotoxin-induced serum factor that causes necrosis of tumors., 10.1073/pnas.72.9.3666
  78. van Horssen R., TNF-  in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility, 10.1634/theoncologist.11-4-397
  79. Balkwill Frances, Tumour necrosis factor and cancer, 10.1038/nrc2628
  80. Cantaert Tineke, Baeten Dominique, Tak Paul P, van Baarsen Lisa GM, Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance, 10.1186/ar3150
  81. Tracey Daniel, Klareskog Lars, Sasso Eric H., Salfeld Jochen G., Tak Paul P., Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, 10.1016/j.pharmthera.2007.10.001
  82. Wei Yonggang, Liu Fei, Li Bo, Chen Xi, Ma Yu, Yan Lvnan, Wen Tianfu, Xu Mingqing, Wang Wentao, Yang Jiayin, Polymorphisms of Tumor Necrosis Factor-Alpha and Hepatocellular Carcinoma Risk: A HuGE Systematic Review and Meta-Analysis, 10.1007/s10620-011-1617-y
  83. Yang Yu, Luo Chao, Feng R., Bi Sheng, The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis, 10.1007/s00432-010-0959-8
  84. Skibola C. F., Bracci P. M., Nieters A., Brooks-Wilson A., de Sanjose S., Hughes A. M., Cerhan J. R., Skibola D. R., Purdue M., Kane E., Lan Q., Foretova L., Schenk M., Spinelli J. J., Slager S. L., De Roos A. J., Smith M. T., Roman E., Cozen W., Boffetta P., Kricker A., Zheng T., Lightfoot T., Cocco P., Benavente Y., Zhang Y., Hartge P., Linet M. S., Becker N., Brennan P., Zhang L., Armstrong B., Smith A., Shiao R., Novak A. J., Maynadie M., Chanock S. J., Staines A., Holford T. R., Holly E. A., Rothman N., Wang S. S., Tumor Necrosis Factor (TNF) and Lymphotoxin-  (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium, 10.1093/aje/kwp383
  85. Fang Fang, Yao Lei, Yu Xiao Jia, Yu Lu, Wu Qi, Yu Long, TNFα −308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls, 10.1007/s10549-009-0698-1
  86. Zhang Jiyuan, Dou Chao, Song Yuting, Ji Chaoneng, Gu Shaohua, Xie Yi, Mao Yumin, Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis, 10.1007/s10038-008-0273-3
  87. Taylor Peter C, Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases, 10.1016/j.coph.2010.01.005
  88. Lin Jan, Ziring David, Desai Sheetal, Kim Sungjin, Wong Maida, Korin Yael, Braun Jonathan, Reed Elaine, Gjertson David, Singh Ram Raj, TNFα blockade in human diseases: An overview of efficacy and safety, 10.1016/j.clim.2007.08.012
  89. Bickston Stephen J., Lichtenstein Gary R., Arseneau Kristen O., Cohen Roger B., Cominelli Fabio, The relationship between infliximab treatment and lymphoma in Crohn's disease, 10.1016/s0016-5085(99)70294-5
  90. Brown S. Lori, Greene Mark H., Gershon Sharon K., Edwards Evelyne T., Braun M. Miles, Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration, 10.1002/art.10679
  91. Wolfe Frederick, Michaud Kaleb, Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, 10.1002/art.20311
  92. Wolfe Frederick, Michaud Kaleb, Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study, 10.1002/art.22864
  93. Wolfe Frederick, Michaud Kaleb, The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation, 10.1002/art.22579
  94. Bongartz Tim, Sutton Alex J., Sweeting Michael J., Buchan Iain, Matteson Eric L., Montori Victor, Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies : Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials, 10.1001/jama.295.19.2275
  95. Peyrin–Biroulet Laurent, Deltenre Pierre, de Suray Nicolas, Branche Julien, Sandborn William J., Colombel Jean–Frédéric, Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, 10.1016/j.cgh.2008.03.014
  96. Leombruno J P, Einarson T R, Keystone E C, The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, 10.1136/ard.2008.091025
  97. Bongartz T, Warren F C, Mines D, Matteson E L, Abrams K R, Sutton A J, Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials, 10.1136/ard.2008.094904
  98. Siegel Corey A., Marden Sadie M., Persing Sarah M., Larson Robin J., Sands Bruce E., Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis, 10.1016/j.cgh.2009.01.004
  99. Mariette X., Matucci-Cerinic M., Pavelka K., Taylor P., van Vollenhoven R., Heatley R., Walsh C., Lawson R., Reynolds A., Emery P., Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, 10.1136/ard.2010.149419
  100. Dommasch Erica D., Abuabara Katrina, Shin Daniel B., Nguyen Josephine, Troxel Andrea B., Gelfand Joel M., The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials, 10.1016/j.jaad.2010.09.734
  101. Askling Johan, Fahrbach Kyle, Nordstrom Beth, Ross Susan, Schmid Christopher H., Symmons Deborah, Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data, 10.1002/pds.2046
  102. Lopez-Olivo Maria A., Tayar Jean H., Martinez-Lopez Juan A., Pollono Eduardo N., Cueto Jose Polo, Gonzales-Crespo M. Rosa, Fulton Stephanie, Suarez-Almazor Maria E., Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy : A Meta-analysis, 10.1001/2012.jama.10857
  103. Moulis Guillaume, Sommet Agnès, Béné Johana, Montastruc François, Sailler Laurent, Montastruc Jean-Louis, Lapeyre-Mestre Maryse, Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses, 10.1371/journal.pone.0048991
  104. Askling Johan, van Vollenhoven Ronald F., Granath Fredrik, Raaschou Pauline, Fored C. Michael, Baecklund Eva, Dackhammar Christina, Feltelius Nils, Cöster Lars, Geborek Pierre, Jacobsson Lennart T., Lindblad Staffan, Rantapää-Dahlqvist Solbritt, Saxne Tore, Klareskog Lars, Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment? : Anti-TNFα Therapy and Risk of Cancer, 10.1002/art.24941
  105. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot J M, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P, Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry, 10.1136/ard.2009.117762
  106. Deepak Parakkal, Sifuentes Humberto, Sherid Muhammed, Stobaugh Derrick, Sadozai Yama, Ehrenpreis Eli Daniel, T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study, 10.1038/ajg.2012.334
  107. Goffe Bernard, Papp Kim, Gratton David, Krueger Gerald G., Darif Mohamed, Lee Sophia, Bozic Carmen, Sweetser Marianne T., Ticho Barry, An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy, 10.1016/j.clinthera.2005.12.007
  108. Slimani Samy, Lukas Cédric, Combe Bernard, Morel Jacques, Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort, 10.1016/j.jbspin.2010.11.012
  109. Tarella Corrado, Passera Roberto, Magni Michele, Benedetti Fabio, Rossi Andrea, Gueli Angela, Patti Caterina, Parvis Guido, Ciceri Fabio, Gallamini Andrea, Cortelazzo Sergio, Zoli Valerio, Corradini Paolo, Carobbio Alessandra, Mulé Antonino, Bosa Marco, Barbui Anna, Di Nicola Massimo, Sorio Marco, Caracciolo Daniele, Gianni Alessandro M., Rambaldi Alessandro, Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma, 10.1200/jco.2010.28.9777
  110. Buch Maya H, Vital Edward M, Emery Paul, Abatacept in the treatment of rheumatoid arthritis, 10.1186/ar2416
  111. Simon T A, Smitten A L, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg M C, Qi K, Suissa S, Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment, 10.1136/ard.2008.097527
  112. GENOVESE M. C., SCHIFF M., LUGGEN M., LE BARS M., ARANDA R., ELEGBE A., DOUGADOS M., Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy, 10.3899/jrheum.111531
  113. Gandhi Mona, Alwawi Eihab, Gordon Kenneth B., Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis, 10.1016/j.sder.2010.02.001
  114. Strangfeld Anja, Hierse Franka, Rau Rolf, Burmester Gerd-Ruediger, Krummel-Lorenz Brigitte, Demary Winfried, Listing Joachim, Zink Angela, Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT, 10.1186/ar2904
  115. Venkiteshwaran Adith, Tocilizumab, 10.4161/mabs.1.5.9497
Bibliographic reference Beyaert, Rudi ; Beaugerie, Laurent ; Van Assche, Gert ; Brochez, Lieve ; Renauld, Jean-Christophe ; et. al. Cancer risk in immune-mediated inflammatory diseases (IMID). In: Molecular Cancer, Vol. 12, no.1, p. 98 [1-12] (2013)
Permanent URL http://hdl.handle.net/2078.1/140347